|
02 Apr 2019 |
TG Therapeutics Reports Positive Interim Data from UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Marginal Zone Lymphoma at the 2019 AACR Annual Meeting
|
|
02 Apr 2019 |
Constellation Pharmaceuticals Presents Results from Phase 1b Portion of ProSTAR Clinical Trial of CPI-1205 at AACR Meeting
|
|
02 Apr 2019 |
Apollomics, Inc. Presents Positive Preclinical Data on APL-102, an oral Multi-Kinase Inhibitor with CSF-1R Activity
|
|
01 Apr 2019 |
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
|
|
01 Apr 2019 |
BerGenBio: Bemcentinib in Combination With low-dose Chemotherapy Achieves Efficacy Endpoint in AML Patients
|
|
01 Apr 2019 |
Biohaven Enrolls First Patient in Phase 2/3 Trial of BHV-3500, Third-Generation CGRP Receptor Antagonist, for the Acute Treatment of Migraine
|
|
01 Apr 2019 |
Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy
|
|
01 Apr 2019 |
Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH
|
|
01 Apr 2019 |
Shionogi Announces Submission of Cefiderocol Marketing Authorisation Application
|
|
01 Apr 2019 |
Selumetinib Granted US Breakthrough Therapy Designation in Neurofibromatosis Type 1
|
|
01 Apr 2019 |
PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome
|
|
01 Apr 2019 |
Peloton Therapeutics Announces Clinical Data Update for PT2977 at European International Kidney Cancer Symposium
|
|
01 Apr 2019 |
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
|
|
01 Apr 2019 |
BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-335140
|
|
01 Apr 2019 |
Recida Therapeutics Announces the Initiation of a Phase I Clinical Trial of RC-01, a Novel LpxC Inhibitor
|
|
30 Mar 2019 |
ESSA Pharma Announces Nomination of EPI-7386 as Lead Clinical Candidate in Metastatic Castration-Resistant Prostate Cancer
|
|
30 Mar 2019 |
Sangamo Therapeutics Presents New Preclinical Data Demonstrating Significant Reduction In Tau Expression With Gene Regulation Technology
|
|
30 Mar 2019 |
Data Safety Monitoring Board Recommends Continuation Of Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
|
|
30 Mar 2019 |
FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis
|
|
30 Mar 2019 |
Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China
|
|
30 Mar 2019 |
Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB)
|
|
30 Mar 2019 |
Gilead and Galapagos Announce Filgotinib Meets Primary and Key Secondary Endpoints in the Phase 3 FINCH 1 Rheumatoid Arthritis Study
|
|
30 Mar 2019 |
Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients
|
|
30 Mar 2019 |
Antibe Therapeutics Announces Commencement of Phase 2B Dose-Ranging, Efficacy Study for Lead Drug, ATB-346
|
|
30 Mar 2019 |
Celgene Receives CHMP Positive Opinions for Both REVLIMID® (lenalidomide) and IMNOVID® (pomalidomide)-Based Triplet Combination Regimens for Patients with Multiple Myeloma
|
